ORCID: https://orcid.org/0000-0001-7077-8078; Erhardt, Franziska; Allgeier, Julian
ORCID: https://orcid.org/0000-0001-7536-5715; Saka, Didem; Donga, Nirali; Neumann, Jens; Lange, Christian M.
ORCID: https://orcid.org/0000-0001-9983-5136 und Gerbes, Alexander L.
(6. Februar 2025):
Drug‐Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern.
In: Liver International, Bd. 45, Nr. 3, e70012
[PDF, 1MB]
Abstract
Background and Aims: Drug-induced liver injury (DILI) due to metamizole has gained increasing attention. Causality assessment remains a challenge, especially in patients with co-medications. We therefore aimed to further characterise metamizole DILI cases.
Methods: The data of patients with metamizole intake from our prospective study on acute liver injury with potential drug-related causes were analysed. Diagnosis and causality assessment were based on a thorough work-up and long-term follow-up.
Results: DILI was associated with metamizole in 61 of 324 DILI patients (prevalence 18.8%). A highly characteristic clinical pattern was observed in 43 of the 61 patients, characterised by marked elevation of transaminases peaking at the time of DILI recognition and a more pronounced increase of bilirubin within the first 3 days of clinical presentation. Patients fitting this picture had higher rates of jaundice, coagulopathy, and acute liver failure, however outcomes did not differ significantly when compared to non-metamizole DILI and autoimmune hepatitis (AIH) patients. Overall, fatal adverse outcomes defined by death or liver transplantation were observed in 13.1% of metamizole DILI patients. On multivariate analysis, only aspartate aminotransferase (AST) and INR were independently associated with a fatal adverse outcome. INR, in particular, performed better than Hy's law, bilirubin, transaminases, and the model for end-stage liver disease (MELD), with a c-statistic of 0.85 (95% CI: 0.70–1.0). At a cut-off of ≥ 2.1, sensitivity and specificity for a fatal adverse outcome were 75% and 96%, respectively.
Conclusions: Metamizole DILI can present with a characteristic pattern that can help clinicians to identify metamizole as the causative agent. Outcome, however, is not associated with this clinical picture and should rather be predicted by INR at onset.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| Fakultät: | Medizin > Klinikum der LMU München > Medizinische Klinik und Poliklinik II (Gastroenterologie, Hepatologie) |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| URN: | urn:nbn:de:bvb:19-epub-129090-9 |
| ISSN: | 1478-3223 |
| Sprache: | Englisch |
| Dokumenten ID: | 129090 |
| Datum der Veröffentlichung auf Open Access LMU: | 29. Okt. 2025 10:32 |
| Letzte Änderungen: | 29. Okt. 2025 10:32 |
